Investment Thesis
RenovoRx is a pre-commercial pharmaceutical company with impressive 85% gross margins but catastrophic operating losses of $3.5M against only $563K in revenue. Despite no debt and a reasonable cash position, the company is burning $3.7M in operating cash flow quarterly with ~3-4 quarters of runway remaining, making near-term viability dependent on achieving critical operational milestones.
Strengths
- Exceptional gross margin of 85.1% demonstrates core product economics are sound
- Strong balance sheet with zero significant debt, $11.3M stockholders equity, and $12.4M cash position
- Explosive revenue growth of +2511.6% YoY indicates emerging market traction despite small absolute base
Risks
- Operating losses of $3.5M dwarf revenue of $563K, indicating company is not near profitability
- Negative operating cash flow of $3.7M per period with estimated 3-4 quarters of cash runway at current burn rate
- Pre-commercial pharma stage with extreme execution risk; success depends on regulatory approval and market adoption
Key Metrics to Watch
- Quarterly revenue growth sustainability and gross margin maintenance as commercialization scales
- Operating cash burn trajectory and cash runway extension through financing or profitability
- Regulatory approval status and clinical development pipeline advancement
Financial Metrics
Revenue
563.0K
Net Income
-3.5M
EPS (Diluted)
$-0.09
Free Cash Flow
-3.7M
Total Assets
14.0M
Cash
12.4M
Profitability Ratios
Gross Margin
85.1%
Operating Margin
-616.2%
Net Margin
-625.4%
ROE
-31.3%
ROA
-25.2%
FCF Margin
-658.8%
Balance Sheet & Liquidity
Current Ratio
7.15x
Quick Ratio
6.95x
Debt/Equity
0.00x
Debt/Assets
19.3%
Interest Coverage
-4.15x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:11:14.548439 |
Data as of: 2026-03-31 |
Powered by Claude AI